Details for Patent: 10,519,146

Which drugs does patent 10,519,146 protect, and when does it expire?

Patent 10,519,146 protects LUMAKRAS and is included in one NDA.

This patent has seventy patent family members in thirty-six countries.

Summary for Patent: 10,519,146

Patent landscape, scope, and claims:

Title:	KRAS G12C inhibitors and methods of using the same
Abstract:	Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
Inventor(s):	Lanman; Brian Alan (Thousand Oaks, CA), Chen; Jian (Thousand Oaks, CA), Reed; Anthony B. (Thousand Oaks, CA), Cee; Victor J. (Thousand Oaks, CA), Liu; Longbin (Thousand Oaks, CA), Kopecky; David John (Thousand Oaks, CA), Lopez; Patricia (Thousand Oaks, CA), Wurz; Ryan Paul (Thousand Oaks, CA), Nguyen; Thomas T. (Thousand Oaks, CA), Booker; Shon (Thousand Oaks, CA), Nishimura; Nobuko (Thousand Oaks, CA), Shin; Youngsook (Thousand Oaks, CA), Tamayo; Nuria A. (Thousand Oaks, CA), Allen; John Gordon (Thousand Oaks, CA), Allen; Jennifer Rebecca (Thousand Oaks, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	15/984,855
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound;

Recent additions to Drugs Protected by US Patent 10,519,146

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Amgen Inc	LUMAKRAS	sotorasib	TABLET	214665	May 28, 2021	RX	Yes	10,519,146	Y	Y
Amgen Inc	LUMAKRAS	sotorasib	TABLET	214665	Jun 26, 2024	RX	Yes	10,519,146	Y	Y
Amgen Inc	LUMAKRAS	sotorasib	TABLET	214665	Jan 20, 2023	RX	Yes	10,519,146	Y	Y

Drugs Protected by US Patent 10,519,146

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-001	May 28, 2021		RX	Yes	No	10,519,146		Y	Y
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-003	Jun 26, 2024		RX	Yes	No	10,519,146		Y	Y
Amgen Inc	LUMAKRAS	sotorasib	TABLET;ORAL	214665-002	Jan 20, 2023		RX	Yes	Yes	10,519,146		Y	Y

International Family Members for US Patent 10,519,146

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	111882
Argentina	122783
Argentina	122784